Opinion|Videos|October 28, 2024
Optimizing Multidisciplinary Care for BCG-Naive, High-Risk NMIBC
Key Takeaways
- Multidisciplinary teams should integrate oncologists and urologists, emphasizing patient-centered care for high-risk non–muscle-invasive bladder cancer.
- Global preparation involves understanding diverse market needs and ensuring access to resources and education.
Panelists discuss the characteristics of an ideal multidisciplinary team for managing BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC), emphasizing the need for oncologists and urologists to collaboratively prepare for successful patient outcomes across different markets, while also identifying necessary educational resources and highlighting adverse events that require attention in preparation for product launches.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What does an ideal multidisciplinary team look like in BCG-naive, high-risk non–muscle-invasive bladder cancer? How can the team (oncologists & urologists) prepare globally (in different markets) to set up patients for the most success?
- What education or resources are needed prior to the launch of these products or prior to this evolving landscape to prepare for the launches?
- What adverse events need attention and education as part of the prelaunch preparation?
- Closing thoughts from each of the panelists.
Advertisement
Related to this article
VOLGA results raise the question of treatment de-intensification in perioperative MIBC care, according to Suzanne B. Merrill, MD, FACS.
Virtuoso Surgical expects to initiate a focused US launch at leading urology centers in 2027.
Pasritamig is being evaluated with or without JNJ-9401 in the ongoing phase 3 KLK2-comPAS trial.
The combination of nogapendekin alfa inbakicept plus BCG demonstrated a statistically significant improvement in efficacy vs BCG alone.
These FAQs outline key recommendations from ASTRO's updated guideline on shorter-course radiation therapy for localized prostate cancer.
Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.
Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.
BCG monotherapy and a high-quality TURBT remain the foundation for BCG-naive high-risk NMIBC, according to Vignesh T. Packiam, MD.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
2
Pasritamig combination yields 73% PSA response rate in phase 1 mCRPC study
3
FAQ: ASTRO guideline on hypofractionated radiation therapy for localized prostate cancer
4
Q&A: Suzanne B. Merrill, MD, FACS, on perioperative therapy in MIBC
5